C WorldWide Group Holding A S lessened its holdings in Portola Pharmaceuticals Inc (NASDAQ:PTLA) by 14.8% during the fourth quarter, HoldingsChannel reports. The firm owned 104,671 shares of the biopharmaceutical company’s stock after selling 18,130 shares during the quarter. C WorldWide Group Holding A S’s holdings in Portola Pharmaceuticals were worth $5,095,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. QS Investors LLC purchased a new stake in Portola Pharmaceuticals in the 2nd quarter valued at approximately $147,000. Oppenheimer Asset Management Inc. boosted its holdings in Portola Pharmaceuticals by 251.2% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 2,862 shares of the biopharmaceutical company’s stock valued at $155,000 after purchasing an additional 2,047 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Portola Pharmaceuticals by 54.9% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,219 shares of the biopharmaceutical company’s stock valued at $157,000 after purchasing an additional 1,141 shares in the last quarter. Canada Pension Plan Investment Board purchased a new stake in Portola Pharmaceuticals in the 3rd quarter valued at approximately $178,000. Finally, Sei Investments Co. purchased a new stake in Portola Pharmaceuticals in the 3rd quarter valued at approximately $217,000. 87.29% of the stock is currently owned by institutional investors.

Shares of Portola Pharmaceuticals Inc (NASDAQ PTLA) opened at $44.41 on Friday. The company has a market capitalization of $2,880.00, a P/E ratio of -10.28 and a beta of 1.18. The company has a debt-to-equity ratio of 0.24, a quick ratio of 8.31 and a current ratio of 8.31. Portola Pharmaceuticals Inc has a 52 week low of $26.94 and a 52 week high of $67.10.

In other news, Director Henry Ward Wolff sold 12,000 shares of the business’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $47.00, for a total transaction of $564,000.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 5.50% of the stock is owned by insiders.

PTLA has been the topic of a number of analyst reports. Oppenheimer set a $80.00 price objective on Portola Pharmaceuticals and gave the company a “buy” rating in a report on Monday, January 15th. Goldman Sachs Group started coverage on Portola Pharmaceuticals in a research note on Friday, December 1st. They set a “buy” rating and a $75.00 price target on the stock. BidaskClub lowered Portola Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, December 7th. Citigroup reissued a “buy” rating and set a $74.00 price target on shares of Portola Pharmaceuticals in a research note on Thursday, December 28th. Finally, Zacks Investment Research raised Portola Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, January 10th. One analyst has rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $70.65.

TRADEMARK VIOLATION NOTICE: “C WorldWide Group Holding A S Has $5.10 Million Holdings in Portola Pharmaceuticals Inc (PTLA)” was first published by Daily Political and is the property of of Daily Political. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. & international copyright law. The original version of this article can be viewed at https://www.dailypolitical.com/2018/02/10/c-worldwide-group-holding-a-s-has-5-10-million-holdings-in-portola-pharmaceuticals-inc-ptla.html.

Portola Pharmaceuticals Profile

Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.

Want to see what other hedge funds are holding PTLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Portola Pharmaceuticals Inc (NASDAQ:PTLA).

Institutional Ownership by Quarter for Portola Pharmaceuticals (NASDAQ:PTLA)

Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.